Close Menu

NEW YORK ─ Epigenetic diagnostics firm VolitionRx on Wednesday announced it has been awarded additional non-dilutive funding totaling approximately $4 million from the government of the Walloon Region and venture capital investor Namur Invest, both in Belgium, consisting of a cash grant of $1.3 million and $2.7 million in loans.

Volition obtained the cash grant from the Walloon Region to support a project titled Epigenetic Modifications of Nucleosomes Associated With Cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.